A personalized mRNA cancer vaccine developed by Moderna and Merck — when combined with the immunotherapy drug Keytruda — ...
Researchers found that Keytruda — the focus of ICIJ's recent Cancer Calculus investigation — accounted for nearly half of the ...
A recent cross-border investigation examines how aggressive drug pricing and patent strategies drive up costs and limit ...
The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...
Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...
Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma. The combination ...
Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...
Moderna and Merck's cancer vaccine, used in combination with Merck's Keytruda, reduced the risk of melanoma spreading to other parts of the body or death by 65% compared with Keytruda alone. Melanoma ...
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results